The main steps in the development of anticancer agents

G. Schwartsmann; B. Winograd; H. M. Pinedo

doi:10.1016/0167-8140(88)90020-5

The main steps in the development of anticancer agents

G. Schwartsmann, B. Winograd, H. M. Pinedo

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

The development of new anticancer agents is a long-term process, which involves the acquisition of new compounds, screening for antitumor activity, production and formulation, animal toxicology and finally, evaluation of toxicity and antitumor activity of the compound in man (Table I). In this paper, the main steps in the early development of new cytotoxic agents up to phase II clinical studies will be discussed. However, clinical phase III-IV trials, where the efficacy of the drug has been proven, should be dealth with separately.

Original language	English (US)
Pages (from-to)	301-313
Number of pages	13
Journal	Radiotherapy and Oncology
Volume	12
Issue number	4
DOIs	https://doi.org/10.1016/0167-8140(88)90020-5
State	Published - 1988
Externally published	Yes

Keywords

Anticancer agents
Clinical trials
Drug development

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Urology

Access to Document

10.1016/0167-8140(88)90020-5

Cite this

@article{09557a00687c4d6fb23efa36b3c77bcc,

title = "The main steps in the development of anticancer agents",

abstract = "The development of new anticancer agents is a long-term process, which involves the acquisition of new compounds, screening for antitumor activity, production and formulation, animal toxicology and finally, evaluation of toxicity and antitumor activity of the compound in man (Table I). In this paper, the main steps in the early development of new cytotoxic agents up to phase II clinical studies will be discussed. However, clinical phase III-IV trials, where the efficacy of the drug has been proven, should be dealth with separately.",

keywords = "Anticancer agents, Clinical trials, Drug development",

author = "G. Schwartsmann and B. Winograd and Pinedo, {H. M.}",

year = "1988",

doi = "10.1016/0167-8140(88)90020-5",

language = "English (US)",

volume = "12",

pages = "301--313",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "4",

}

TY - JOUR

T1 - The main steps in the development of anticancer agents

AU - Schwartsmann, G.

AU - Winograd, B.

AU - Pinedo, H. M.

PY - 1988

Y1 - 1988

N2 - The development of new anticancer agents is a long-term process, which involves the acquisition of new compounds, screening for antitumor activity, production and formulation, animal toxicology and finally, evaluation of toxicity and antitumor activity of the compound in man (Table I). In this paper, the main steps in the early development of new cytotoxic agents up to phase II clinical studies will be discussed. However, clinical phase III-IV trials, where the efficacy of the drug has been proven, should be dealth with separately.

AB - The development of new anticancer agents is a long-term process, which involves the acquisition of new compounds, screening for antitumor activity, production and formulation, animal toxicology and finally, evaluation of toxicity and antitumor activity of the compound in man (Table I). In this paper, the main steps in the early development of new cytotoxic agents up to phase II clinical studies will be discussed. However, clinical phase III-IV trials, where the efficacy of the drug has been proven, should be dealth with separately.

KW - Anticancer agents

KW - Clinical trials

KW - Drug development

UR - http://www.scopus.com/inward/record.url?scp=0023675958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023675958&partnerID=8YFLogxK

U2 - 10.1016/0167-8140(88)90020-5

DO - 10.1016/0167-8140(88)90020-5

M3 - Article

C2 - 3055073

AN - SCOPUS:0023675958

SN - 0167-8140

VL - 12

SP - 301

EP - 313

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 4

ER -

The main steps in the development of anticancer agents

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this